Here are sales figures for the third quarter for top-selling Pfizer prescription drugs:
PRODUCT NAME MAIN CONDITION/USE 3Q 2011 SALES 3Q 2010 SALES PERCENT CHANGE
Lipitor High cholesterol $2.6 billion $2.53 billion up 3 percent
Prevnar 13 Pneumococcal vaccine $1.01 billion $735 million up 37 percent
Enbrel (outside U.S.) Rheumatoid arthritis $957 million $799 million up 20 percent
Lyrica Fibromyalgia/pain $961 million $757 million up 27 percent
Celebrex Pain $643 million $578 million up 11 percent
Viagra Erectile dysfunction $493 million $459 million up 7 percent
Norvasc High blood pressure $350 million $330 million up 6 percent
Zyvox MRSA infections $321 million $285 million up 13 percent
Xalatan Glaucoma $277 million $416 million down 33 percent
Sutent Multiple cancers $298 million $257 million up 16 percent
Note: Sales changes include favorable benefit from currency exchange rates.
Source: Pfizer Inc.
Throwing rocks in the Granite State
Yahoo editor 'pretty sure' Rubio wrong about Roe v. Wade
Cruz Easily Won the New Hampshire GOP Debate | RedState
Heroin: Blame It On America | Human Events
When Guns Are Outlawed...
Mike Shedlock - Obama Slashes Four Hours Off Definition of "Full-Time" Employment
Analysis: Governors Soar, Rubio Stumbles Early On in Crucial New Hampshire Debate